Quoin Pharma Files US Patent Application For Novel Topical Formulations To Treat Skin Diseases

(RTTNews) - Specialty pharmaceutical company Quoin Pharmaceuticals Ltd. (QNRX) announced Tuesday it has filed a U.S. patent application for novel topical formulations to treat a number of skin diseases, including Netherton Syndrome (NS).

Quoin's lead product, QRX003, is currently being tested in four Netherton Syndrome clinical trials. Three of these trials are being conducted under Quoin's open Investigational New Drug (IND) application with the US Food and Drug Administration (FDA).

QRX003 is also currently being tested in a pediatric NS patient at the Children's Hospital in Dublin, Ireland and the Company intends to expand this study to include additional children with NS in Spain, the United Kingdom and potentially other countries.

This patent application also includes Peeling Skin Syndrome for which Quoin has an ongoing Investigator Clinical Study in a pediatric patient in New Zealand. There are currently no FDA approved treatments for either NS or Peeling Skin Syndrome.

Quoin is currently enrolling patients in three clinical trials being conducted under its open Investigational New Drug (IND) application, evaluating its QRX003 topical lotion as a potential treatment for NS as well as in an Investigator led pediatric study.

To date, Quoin remains the only company actively recruiting and testing subjects in multiple NS clinical trials that are being conducted under an open IND.